Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q15466
UPID:
NR0B2_HUMAN
Alternative names:
Orphan nuclear receptor SHP; Small heterodimer partner
Alternative UPACC:
Q15466; F1D8P5; Q5QP36
Background:
Nuclear receptor subfamily 0 group B member 2, also known as Orphan nuclear receptor SHP or Small heterodimer partner, plays a crucial role in regulating receptor-dependent signaling pathways. It acts as a negative regulator, inhibiting transactivation of nuclear receptors and transcriptional activities of various genes, including those involved in hepatic lipid metabolism and cytochrome P450 enzyme expression.
Therapeutic significance:
Given its essential role in lipid metabolism and enzyme regulation, understanding the role of Nuclear receptor subfamily 0 group B member 2 could open doors to potential therapeutic strategies for obesity, a condition linked to excessive body fat accumulation.